Compositions and methods to improve nanoparticle distribution within the brain interstitium
Improved distribution can be achieved by delivering nanoparticles possessing non-adhesive surfaces via CED in a hyperosmolar infusate solution. This delivery strategy minimizes the hindrances imposed by the brain extracellular matrix and reduces the concentration of therapeutic that is confined within perivascular spaces.
1. A composition for delivery of nanoparticles to tissues including brain, the composition comprising
(i) a hyperosmolar solution for a tissue to which it is to be administered having a salt concentration between 1% and 10% NaCl; and
(ii) nanoparticles comprising
a first polymer selected from the group consisting of poly(hydroxy acids), polyanhydrides, poly(ortho)esters, polyurethanes, polyesters, poly(amine-co-ester), polyhydroxyalkanoates, blends and copolymers thereof, and
a second hydrophilic, neutrally charged polyalkylene glycol polymer, covalently linked to the first polymer to form a polymer conjugate,
wherein the second hydrophilic and neutrally charged polymer forms a coating on the surface of the nanoparticles and the first polymer forms the core of the nanoparticles,
wherein the concentration of the hyperosmolar solution and the density of the hydrophilic, neutrally charged polymer in the surface coating are in amounts effective to enhance the diffusion and distribution of the nanoparticles within tissues, and
wherein the density of the hydrophilic, neutrally charged polyalkylene glycol polymer on the surface of the nanoparticles is at least 0.01 units/nm 2 .
2. The composition of claim 1 , for delivery into the brain parenchyma.
3. The composition of claim 1 , wherein the nanoparticles have a diameter of less than or equal to 114 nm, 80 nm, or 60 nm.
4. The composition of claim 1 , wherein the second hydrophilic polymer is selected from the group consisting of polyethylene glycol, polysorbate 80, polyethylene glycol-polyoxyethylene, and combinations thereof.
5. The composition of claim 4 , wherein the second hydrophilic polymer is polyethylene glycol having a molecular weight between 1,000 Daltons and 10,000 Daltons.
6. The composition of claim 5 , wherein the polyethylene glycol has a molecular weight of 5,000 Daltons.
7. The composition of claim 6 , wherein the first polymer is selected from the group consisting of poly(hydroxy acids), polyanhydrides, poly(ortho)esters, polyhydroxyalkanoates, blends and copolymers thereof.
8. The composition of claim 7 , wherein the poly(hydroxy acid) is poly(lactide-co-glycolic acid).
9. The composition of claim 1 , wherein the concentration of the sodium chloride in the saline solution is 3%.
10. The composition of claim 1 , wherein the weight percent of the second hydrophilic polymer relative to total nanoparticle is at least 80%.
11. The composition of claim 1 , wherein the weight percent of the second hydrophilic polymer relative to the weight of the polymer conjugate is at least 25%.
12. A dosage formulation for delivery of a therapeutic, prophylactic or diagnostic agent to the brain, consisting of
an effective amount of the compositions of claim 1 for administration to the brain.
13. The formulation of claim 12 , wherein the compositions are formulated for direct administration to the brain using convection enhanced delivery.
14. A method for treating one or more symptoms of a disease or disorder of the brain, comprising administering to the brain a formulation comprising
a therapeutically effective amount of the composition of claim 1 .
15. The method of claim 14 , wherein the formulation is administered to the brain using convection enhanced delivery.
16. The method of claim 15 , wherein the composition is administered in combination with one or more techniques to facilitate passage of the particles through the blood brain barrier.